At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
Fexofenadine 180 mg tablets +1 moredrug
Likely dose
Fexofenadine 180 mg tabletsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Relative Bioavailability Study of 180 mg Fexofenadine Hydrochloride Tablets Under Fed Conditions.
In Brief
A Phase 1 clinical trial evaluating Fexofenadine 180 mg tablets and ALLEGRA® 180 mg tablets for Healthy. Completed, enrolled 24 participants across 1 site.
Detailed Summary
This study will compare the relative bioavailability (rate and extent of absorption) of 180 mg Fexofenadine Hydrochloride tablets manufactured for TEVA Pharmaceuticals Industries, Ltd. with that of 180 mg ALLEGRA® Tablets by Aventis Pharmaceuticals, Inc. following a single oral dose (1 x 180 mg tablet) in healthy adult volunteers under fed conditions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2002
Primary CompletionJan 2002
First PostedFeb 2009
TodayJul 2026
First PostedFeb 3, 2009
Enrollment StartJan 1, 2002
Primary CompletionJan 1, 2002
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 17.4 years ago
Interventions
Fexofenadine 180 mg tabletsdrug
1 x 180 mg
ALLEGRA® 180 mg tabletsdrug
1 x 180 mg